The Reporting of Harms in Randomized Controlled Trials of Hypertension Using the CONSORT Criteria for Harm Reporting

被引：22
作者：
Bagul, Nitin Babulal [1 ]
Kirkham, Jamie J. [2 ]
机构：
[1] Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England
[2] Univ Liverpool, Dept Biostat, Liverpool L69 3GS, Merseyside, England
来源：
CLINICAL AND EXPERIMENTAL HYPERTENSION | 2012年 / 34卷 / 08期
关键词：
harm; adverse event; CONSORT; CONSORT extension; drug safety; ADVERSE EVENTS; QUALITY; STATEMENT; IMPROVE;
D O I：
10.3109/10641963.2012.681724
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The aim of this study was to assess the quality of reporting of harms in hypertension clinical trials identified from the Cochrane Database using the Consolidated Standards of Reporting Trials (CONSORT) extension for harms reporting. Forty-one hypertension trials were included in the study. On average trials reported less than half of the items recommended by the CONSORT extension for harms (mean 9.83 items; 95% confidence interval 8.06, 11.60). Trialists need to address the perceived shortcomings in measurement, analysis, and reporting of harms data so that the available trial data can be considered as a balanced and reliable source of evidence.
引用
收藏
页码：548 / 554
页数：7
相关论文
共 18 条
  • [1] Improving the quality of reporting of randomized controlled trials - The CONSORT statement
    Begg, C
    Cho, M
    Eastwood, S
    Horton, R
    Moher, D
    Olkin, I
    Pitkin, R
    Rennie, D
    Schulz, KF
    Simel, D
    Stroup, DF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08): : 637 - 639
  • [2] Reporting of harms and adverse events in otolaryngology journals
    Bibawy, Haidy
    Cossu, Anne
    Cogan, Sophia
    Rosenfeld, Richard
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2009, 140 (02) : 241 - 244
  • [3] Reporting of Harm in Randomized Controlled Trials Published in the Urological Literature
    Breau, Rodney H.
    Gaboury, Isabelle
    Scales, Charles D., Jr.
    Fesperman, Susan F.
    Watterson, James D.
    Dahm, Philipp
    [J]. JOURNAL OF UROLOGY, 2010, 183 (05) : 1693 - 1697
  • [4] Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review
    Chowers, Michal Y.
    Gottesman, Bat Sheva
    Leibovici, Leonard
    Pielmeier, Ulrike
    Andreassen, Steen
    Paul, Mical
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) : 239 - 250
  • [5] Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease
    Ethgen, M
    Boutron, I
    Baron, G
    Giraudeau, B
    Sibilia, J
    Ravaud, P
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (01) : 20 - 25
  • [6] Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention
    Ethgen, Morgane
    Boutron, Isabelle
    Steg, Philippe Gabriel
    Roy, Carine
    Ravaud, Philippe
    [J]. TRIALS, 2009, 10
  • [7] The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry
    Han, Changsu
    Kwak, Kyung-phil
    Marks, David M.
    Pae, Chi-Un
    Wu, Li-Tzy
    Bhatia, Karnal S.
    Masand, Prakash S.
    Patkar, Ashwin A.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2009, 30 (02) : 116 - 122
  • [8] Better reporting of harms in randomized trials: An extension of the CONSORT statement
    Ioannidis, JPA
    Evans, SJW
    Gotzsche, PC
    O'Neill, RT
    Altman, DG
    Schulz, K
    Moher, D
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) : 781 - 788
  • [9] The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews
    Kirkham, Jamie J.
    Dwan, Kerry M.
    Altman, Douglas G.
    Gamble, Carrol
    Dodd, Susanna
    Smyth, Rebecca
    Williamson, Paula R.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 : 637 - 640
  • [10] Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3
12